ClinicalTrials.gg
Active, not recruitingNCT07290413Updated Dec 18, 2025

Photobiomodulation for the Prevention of Oral Mucositis

A Phase 2 interventional study of Photobiomodulation - INTRAORAL and Photobiomodulation - EXTRAORAL in Oral Mucositis, sponsored by Brigham and Women's Hospital. Active, not recruiting at 1 site in United States. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by Brigham and Women's Hospital · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
4 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Stomatitis with a site in United States — 12 open to participants now, 15 under way, none of them phase 3. Stomatitis · United States.

Planned enrollment
29th of 73
78 · median 60
Started
2025
with 1 other
Phase 2
33 of 80
2 open now
Primary completion
2026-12
later than 3 of 14 live
Registered
75th of 80
by date

Among the 80 studies in Stomatitis with a site in United States, this one is the 29th largest by planned enrollment of the 73 interventional ones that give a count, is one of 2 that started in 2025, is one of 33 in phase 2, reaches primary completion later than 3 of the 14 other live ones, and was the 75th registered.

Stomatitis

307 studies on the registry are indexed under Stomatitis; 74 are open to participants now.

Browse Stomatitis studies →

Open to participants now

12 of the 80 studies in Stomatitis with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 45 Stomatitis studies recruiting now, 20 (44%) set no upper age limit and 21 (47%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.

This study: 4 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Stomatitis with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if photobiomodulation works to prevent severe oral mucositis in patients who are undergoing allogeneic hematopoietic cell transplantation. The main questions it aims to answer are:

Does 1) intraoral , 2) extraoral, or 3) combined intraoral/extraoral photobiomodulation have optimal prevention/therapeutic effect in prevention of oral mucositis in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation (alloHSCT).

Participants will:

Be randomized to one of the three treatment arms Receive daily photobiomodulation therapy (from beginning of transplant conditioning through Day +20 after transplantation) Be evaluated for oral mucositis and symptoms daily Visit the clinic once every 2 weeks for checkups and tests Keep a diary of their symptoms and the number of times they use a rescue inhaler

Read the detailed description

Patients who are planned for alloHSCT will be randomized 1:1:1 to one of the 3 treatment arms, stratified by age (\<18, ≥ 18years). This is a phase 2 randomized trial to identify which of the three photobiomodulation therapy (PBMT) devices, 1) intraoral , 2) extraoral, and 3) combined intraoral/extraoral, has optimal prevention/therapeutic effect in prevention of oral mucositis in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation (alloHSCT). The study will be conducted in parallel, in a quasi-multi-center manner at three other alloHSCT centers (AC Camargo, SP, Brazil; Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Cincinnati Children's Hospital Medical Center; in addition to DFCI/BWH).

Participants will be evaluated daily according to the validated WHO Oral Toxicity Scale by trained and calibrated investigators. Within each arm, a Simon's 2 stage design will be applied in an intention to treat analysis of the proportion of patients who have \<5 days of WHO grade ≥ 3 OM, to eliminate arms with insufficient evidence of efficacy. The remaining arms will be analyzed in a selection design (pick the winner) to determine the probability that the arm selected for a future phase 3 trial is either superior to, or at worst, more or less equivalent to, other arm(s). The study will enroll up to 96 patients with up to 26 patients per treatment arm. The accrual rate at DFCI is anticipated to be 2 patients/month, or 24 patients per year. The same accrual rate is anticipated at each of the other three study sites. Therefore, the total accrual of 78 patients can be achieved within 1 year.

The primary endpoint, duration of severe OM, is defined in section 11.1 as the total number of days between day 0 and day +20 on which severe (WHO grade 3 or 4) OM was reported. A conservative approach to missing data will be taken: Any day on which the grading of mucositis is missing will be counted as a day with WHO grade ≥3 OM. Each patient will be classified as either a success or a failure. "Success" will be defined as a patient who has a duration of WHO grade ≥3 OM \<5 days; a patient with ≥5 days will be classified as a "failure" (i.e., a binary endpoint).

The secondary endpoints that will be subjectively considered in making the final selection of the winning arm are:

  • Adverse events attributed to PBMT administration;
  • Patient acceptability of the PBMT administration;
  • Operator acceptability of the PBMT administration;
  • Duration of time to complete PBMT administration;
  • Duration of hospital stay; and,
  • Need to initiate parenteral nutrition.
03

Conditions studied

  • Oral Mucositis

Browse trials for

04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Planned to undergo myeloablative HCT (with one of the following regimens): FluBu4, FluMel, or CyTBI conditioning and Tac-Mtx prophylaxis
  • Age ≥4 years
  • Ability to understand and the willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  • Participants who have had treatment with oral PBMT within four weeks of admission for .
  • Participants who have a history of radiation therapy to the head and neck.
  • Participants who have a history of photosensitivity or underlying disease with known photosensitivity.
  • Participants who are planned to receive palifermin (keratinocyte growth factor) for OM prevention.
  • Participants who have facial hair and unwilling to shave.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    Intraoral photobiomodulation

    Intraoral PBMT device: The THOR intraoral PBMT device emits LED light with an irradiance of 50 mW/cm2 and, when applied for 60 seconds, delivers 3 J/cm2. It is a handheld device with an array of LEDs covered by smooth glass. The therapeutic area is small enough (similar to a popsicle) to place in the mouth comfortably.

    Device: Photobiomodulation - INTRAORAL

  • Experimental
    Extraoral photobiomodulation

    Extraoral PBMT device: The extraoral PBMT device is a dual headed probe designed to be connected to the LX2.3 Laser and LED Therapy System. It consists of two high-powered probes designed to emit 850nm light at an intensity of 240 m/cm2. The device is dual-headed in order to treat both sides of the head simultaneously without the need for a sperate control unit.

    Device: Photobiomodulation - EXTRAORAL

  • Experimental
    Combined intraoral and extraoral photobiomodulation

    Participants in this arm will receive both intraoral and extraoral photobiomodulation.

    Device: Photobiomodulation - INTRAORAL and EXTRAORAL

Interventions

  • DevicePhotobiomodulation - INTRAORAL

    Participants will receive intraoral photobiomodulation

  • DevicePhotobiomodulation - EXTRAORAL

    Participants will receive extraoral photobiomodulation

  • DevicePhotobiomodulation - INTRAORAL and EXTRAORAL

    Participants will receive intraoral and extraoral photobiomodulation

06

What researchers measure

Primary outcomes

  1. Duration of severe oral mucositis according to the World Health Organization Oral Toxicity Score

    WHO Score (0-4, "severe" defined as grades 3 and 4)

    Time frame: Oral mucositis is assessed daily from day 0 through day +20

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 39 phase 2 interventional studies under Stomatitis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 48. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2025
First posted
Dec 18, 2025
StartActual
Dec 1, 2025
Primary completionEst.
Dec 2026
CompletionEst.
May 2027
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07290413
Responsible party
Nathaniel Simon Treister (Associate Surgeon, Brigham and Women's Hospital) — Principal investigator
First posted
Dec 18, 2025
Start date
Dec 1, 2025
Primary completion
Dec 2026 (estimated)
Completion
May 2027 (estimated)
Last update
Dec 18, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion